Dapagliflozin
|
|
|
- CAS-Nr.
- 461432-26-8
- Englisch Name:
- Dapagliflozin
- Synonyma:
- Dapagliflozin Propanediol Monohydrate;Dapagliflozin propanediol;Farxiga;DAPAGLIFLOZIN BASE;Dapagliflozi;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol;Dagliflozin;Dapgliflozin;D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-;2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
- CBNumber:
- CB91011730
- Summenformel:
- C21H25ClO6
- Molgewicht:
- 408.88
- MOL-Datei:
- 461432-26-8.mol
|
Dapagliflozin Eigenschaften
- Schmelzpunkt:
- 55-58°C
- Siedepunkt:
- 609.0±55.0 °C(Predicted)
- Dichte
- 1.349
- storage temp.
- 2-8°C
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 13.23±0.70(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Pale Yellow
- Optische Rotation
- [α]/D (+7.0° to +13.0°, c = 0.2 in methanol)
- Stabilit?t:
- Hygroscopic
- InChI
- 1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
- InChIKey
- JVHXJTBJCFBINQ-JNTNYNDRNA-N
- SMILES
- O[C@@H]1[C@H]([C@H](O)[C@@H](CO)O[C@H]1C1C=CC(Cl)=C(CC2C=CC(OCC)=CC=2)C=1)O |&1:1,2,3,5,9,r|
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| RIDADR |
UN3077 |
|
|
| WGK Germany |
WGK 3 |
|
|
| HazardClass |
9 |
|
|
| Speicherklasse |
6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects |
|
|
| Hazard Classifications |
Acute Tox. 4 Oral
Aquatic Chronic 2
Eye Irrit. 2
STOT RE 1 |
|
|
| Bildanzeige (GHS) |
  
|
| Alarmwort |
Achtung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H318 |
Verursacht schwere Augensch?den. |
Schwere Augensch?digung |
Kategorie 1 |
Achtung |
|
P280, P305+P351+P338, P310 |
| H372 |
Sch?digt bei Hautkontakt und Verschlucken die Organe bei l?ngerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) |
Kategorie 1 |
Achtung |
|
P260, P264, P270, P314, P501 |
|
| Sicherheit |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P301+P312 |
BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
| P310 |
Sofort GIFTINFORMATIONSZENTRUM/Arzt/ anrufen. |
| P314 |
Bei Unwohlsein ?rztlichen Rat einholen / ?rztliche Hilfe hinzuziehen. |
| P330 |
Mund ausspülen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Dapagliflozin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
The Australian Therapeutic Goods Administration (TGA) and the
European Commission approved dapagliflozin in October and November
2012, respectively, as an adjunct to diet and exercise for the treatment of
type 2 diabetes. Dapagliflozin is a potentially attractive therapy due to its glucosesensitive and insulin-independent mechanism of action. It is a first-in-class
selective SGLT2 inhibitor (IC
50=1.1 nM; selectivity vs. SGLT1 >1000)
that lowers the renal threshold for reabsorption of glucose, allowing excess
glucose to be eliminated via the kidneys. In normal rats, administration of
dapagliflozin promotes dose-dependent excretion of up to 1900 mg of glucose
over a 24 h period, with amaximal effect at 3 mg/kg. In a ratmodel of
diabetes, pretreatment with the pancreatic toxin streptozotocin results in
hyperglycemia that is reduced 55% by administration of a single
0.1 mg/kg dose of dapagliflozin compared with vehicle. Aryl
O-glucoside SGLT2 inhibitors were early entrants into the clinic, but
the aryl C-glucoside linkage found in dapagliflozin confers resistance to
glucosidase-mediated metabolism leading to improved clinical utility relative to aryl O-glucosides. The modified carbohydrate–aglycone linkage
required concomitant adjustment from an ortho- to a meta-substituted
arylglucoside to achieve potent SGLT2 inhibition. Dapagliflozin was
synthesized in several steps via reaction of an aryllithium with per-silylated gluconolactone to form the key C-glucoside linkage. An alpha-selective
reduction of the resultant anomeric glycoside gave the desired beta-Carylglucoside. The main circulating (inactive) metabolite is the result
of 3-O-glucuronidation of the glucosylmoiety. Of the minority metabolites,
the main oxidative species result from O-dealkylation of the ethoxy-group and hydroxylation of the biarylmethane moiety.
Chemische Eigenschaften
White Solid
History
Dapagliflozin (brand name farxiga) was authorized for medical use in the European Union in November 2012. It was approved for medical use in the United States in January 2014.
In 2020, the US FDA expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.
In April 2021, the FDA expanded the indications for dapagliflozin to include reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.
In February 2023, the EU authorized dapagliflozin for extended use to cover heart failure patients across the full spectrum of left ventricular ejection fraction (LVEF), including those with mildly reduced and preserved ejection fraction.
Verwenden
A sodium-glucose transporter 2 inhibitor.
Definition
ChEBI: A C-glycosyl comprising beta-D-glucose in which the anomeric hydroxy group is replaced by a 4-chloro-3-(4-ethoxybenzyl)phenyl group. Used (in the formo f its propanediol monohydrate) to improve glycemic
ontrol, along with diet and exercise, in adults with type 2 diabetes.
Dapagliflozin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Dapagliflozin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 868)Lieferanten
- Dapagliflozin(BMS-512148)
- 1-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-deoxy-beta-D-glucopyranose
(1S)-1,5-Anhydro-1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxyMethyl)tetrahydro-2H-pyran-3,4,5-triol
- (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxyMethyltetrahydro-2H-pyran-3,4,5-triol
- 1-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-deoxy-beta-D-glucopyranose
- BMS5121458
- Dag coluMn net
- Dapagliflozin Isomer Impurity
- Dapagliflozin, >=98%
- DAPAGLIFLOZIN
- BMS-512148-05
- Bms 512148
- apagliflozin
- Dapagliflozin USP/EP/BP
- Dagagflozin
- Dagliejing
- Dapagliflozin S1548 Selleck
- Daglican
- CS-179
- Dagliel
- Dapagli ozin
- Dapagliflozen amorphous
- High Quality Dapagliflozin CAS No. 461432-26-8 with Safe Shipping
- (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hy...
- DapagliflozinQ: What is
Dapagliflozin Q: What is the CAS Number of
Dapagliflozin Q: What is the storage condition of
Dapagliflozin Q: What are the applications of
Dapagliflozin
- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol
- Farxiga
- D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-
- (2S,4R,5R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)tetrahydro-2H-pyran-3,4,5-triol
- 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
- Glenn net
- DAPAGLIFLOZIN（base，Amorphous）
- (1S)-1,5- dehydration -1-C-[4- chloro -3-[(4- ethoxyphenyl) methyl] phenyl ]-D- glucitol
- BMS512148,Sodium-dependent glucose cotransporters,SGLT,BMS 512148,inhibit,Dapagliflozin,Inhibitor
- (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
- Dapagliflozin CRS
- 2-Chloro-5-（ β- D-glucopyrano-1-yl) -4 '- ethoxydiphenylmethane
- Dapagliflozin (Propanediol Monohydrate & Amorphous)
- Dapagliflozin Reference Standard
- Dagliazine
- Dapagliflozin Crude
- Dapagliflozin, 10 mM in DMSO
- Dapagliflozin - Bio-X ?
- (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
- Dapagliflozin, 99%min
- DAPAGLIFLOZIN BASE
- Dapagliflozin (Standard)
- Dagliflozin
- Dapagliflozi
- Dapgliflozin
- Dapagliflozin Propanediol Monohydrate
- Dapagliflozin propanediol
- 461432-26-8
- 461432-26-8;960404-48-2
- 61432-26-8
- 46132-26-8
- 461436-26-8
- C21H25ClO6
- Inhibitors
